{"filing":{"accession_number":"0001104659-26-088461","cik":"0001346830","ticker":"TVRD","company_name":"Tvardi Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"tm2621651d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926088461/tm2621651d1_8k.htm"},"events":[{"id":22076,"run_id":19945,"accession_number":"0001104659-26-088461","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Tvardi announced the selection of ulcerative colitis as the initial indication for its lead candidate TTI-109, following completion of a Phase 1 healthy volunteer study. This represents a material strategic and operational milestone in the company's clinical development pathway—the decision to advance a specific product candidate into a defined therapeutic area with planned IND clearance and Phase 2 initiation in 2027. While not a traditional M\u0026A, earnings, or governance event, this disclosure of a major clinical development decision and the supporting Phase 1 data would affect a reasonable investor's assessment of the company's pipeline progress and near-term catalysts.","company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21909,"accession_number":"0001104659-26-088461","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tvardi announced the selection of ulcerative colitis as the initial indication for its lead candidate TTI-109, following completion of a Phase 1 healthy volunteer study. This represents a material strategic and operational milestone in the company's clinical development pathway—the decision to advance a specific product candidate into a defined therapeutic area with planned IND clearance and Phase 2 initiation in 2027. While not a traditional M\u0026A, earnings, or governance event, this disclosure of a major clinical development decision and the supporting Phase 1 data would affect a reasonable investor's assessment of the company's pipeline progress and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:31:50.901669+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21909,"accession_number":"0001104659-26-088461","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tvardi announced the selection of ulcerative colitis as the initial indication for its lead candidate TTI-109, following completion of a Phase 1 healthy volunteer study. This represents a material strategic and operational milestone in the company's clinical development pathway—the decision to advance a specific product candidate into a defined therapeutic area with planned IND clearance and Phase 2 initiation in 2027. While not a traditional M\u0026A, earnings, or governance event, this disclosure of a major clinical development decision and the supporting Phase 1 data would affect a reasonable investor's assessment of the company's pipeline progress and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:31:50.901669+00:00","company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","filing_date":"2026-07-30"}]}